At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
Guanfacine +1 moredrug
Likely dose
Guanfacine 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Guanfacine (GUA) (3mg/Day) to Reduce Drug Craving, Improve Cognitive Flexibility and Result in Associated Lower Drug Use in Women With Substance Use Disorder (SUD).
In Brief
A Phase 2 clinical trial evaluating Guanfacine and Behavioral Counseling for Substance Use Disorders. Completed, enrolled 74 participants across 1 site.
Detailed Summary
Hypothesis: Guanfacine (GUA) (3mg/day) will reduce drug craving, improve cognitive flexibility and result in associated lower drug use in women with substance use disorder (SUD) in an outpatient clinical setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Use Disorders
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartNov 2019
Primary CompletionNov 2022
TodayJul 2026
First PostedJun 10, 2019
Enrollment StartNov 1, 2019
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.1 years ago
Interventions
Guanfacinedrug
Guanfacine 3mg/day Versus Placebo
Behavioral Counselingother
placebo